News and Trends 26 Jul 2018 Replimune’s €85M IPO set to Boost Oncolytic Immunotherapy Pipeline The US-UK biotech completed its $100M (€85M) IPO on the NASDAQ stock exchange to further develop ‘oncolytic’ immunotherapies that use the herpes virus to target and attack tumor tissue. Replimune’s immunotherapies use the virus to deliver proteins into tumor tissue that help it fuse with the tumor cells. When the virus fuses to tumor cells, it activates […] July 26, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2018 Austrian Researchers Grow Cancerous Mini Brains in a Dish Researchers in Vienna are growing mini brains that mimic the onset and development of brain cancer, which could be used to compare the efficacy of different treatments. Because of their cellular complexity, brain cancers have been difficult to study in animals. Glioblastoma, the most aggressive form of brain cancer, is particularly difficult to treat because […] July 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 24 Jul 2018 Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug” Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […] July 24, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2018 Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […] July 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2018 Radioactive Nanoparticle Could Improve Cancer Diagnoses Isotopia Molecular Imaging, an Israeli company, is developing a radioactive marker made of gold nanoparticles to detect cancer more accurately than with current diagnostic tools. PET and CT scans are two types of X-ray tests that use small quantities of radioactive materials, called contrast agents, to help visualize and assess organ and tissue function. These […] July 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2018 Update: Yet Another ADC Company Makes Bank, This Time in Series B Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […] June 29, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Startup Scout 29 Jun 2018 This French Biotech Links Drugs Together to Target Bone Cancer This week, we’re in Aronnax, France, visiting Atlanthera, a biotech developing more effective treatments for bone cancer using a two-compound approach. Mission: Antlanthera was founded in 2011 with the goal of developing more effective drugs for bone cancer. The company uses biophosphonates, a popular bone-building treatment for osteoporosis, to target bone tissue. Atlanthera’s technology works […] June 29, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […] June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 22 Jun 2018 Swedish Biotech’s Liquid Biopsy Could Improve Accuracy of Cancer Diagnoses Elypta is developing liquid biopsies that analyze cancer metabolism to make cancer diagnoses more accurate. Philip talked to Francesco Gatto, Elypta’s Chief Scientific Officer and a co-founder, on their technology, moving from academia to industry, and the challenges of starting a biotech company. Even though biotechs and pharma companies across the globe have been pouring […] June 22, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2018 Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III Results A nanomedicine designed to help amplify and focus radiation treatment on hard to treat soft tissue sarcoma cells has achieved positive Phase II/III trial results for French-American biotech Nanobiotix. “Data are exceptional and show without any doubt an improvement of radiation therapy impact,” commented Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at […] June 22, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2018 Next-Generation CAR-T Company Raises €130M on NASDAQ IPO London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a next generation of CAR-T cell therapy for cancer. Founded in 2014 as a spin-out from University College London, Autolus has been taking great strides to develop its CAR-T technology. In less than four years, the company managed to raise nearly €150M […] June 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2018 Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic within the next one and a half years. iTeos Therapeutics, a Belgian biotech, raised what may have been the largest Series B financing round in Europe so far this year, led by MPM Capital. The funding will be used to […] June 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email